The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

(2018) Pierre Laneuville   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

(2018) Monica Bocchia et al.   Frontiers in Oncology

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors

(2017) Ami B. Patel et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Abundant expression of BMI1 in follicular lymphoma is associated with reduced overall survival

(2017) Naif AlJohani et al.   LEUKEMIA & LYMPHOMA

Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia

(2017) Ahmed Gamal Elsayed et al.   Current Oncology Reports

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

(2017) Mohammad Alzrigat et al.   Oncotarget

miR-15a/miR-16 down-regulates BMI1, impacting Ub-H2A mediated DNA repair and breast cancer cell sensitivity to doxorubicin

(2017) Nibedita Patel et al.   Scientific Reports

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

(2016) Simona Soverini et al.   BMC CANCER

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization

(2015) Nicholas C. P. Cross et al.   ANNALS OF HEMATOLOGY

Natural course and biology of CML

(2015) Bradley Chereda et al.   ANNALS OF HEMATOLOGY

The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study

(2015) Mohammad Mohammadi et al.   BMC CANCER

gDNA Q-PCR for clinical monitoring of CML

(2015) Giovanni Porta et al.   CELL CYCLE

Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review

(2015) Ke Yang et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients

(2015) Giovanni Caocci et al.   EXPERIMENTAL HEMATOLOGY

Polycomb genes are associated with response to imatinib in chronic myeloid leukemia

(2015) Francesco Crea et al.   Epigenomics

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

(2014) R. Bejar et al.   BLOOD

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

(2014) H. Herrmann et al.   BLOOD

BMI1 gene expression in myeloid leukemias and its impact on prognosis

(2014) Niveen S. Saudy et al.   BLOOD CELLS MOLECULES AND DISEASES

DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia

(2014) Peter Valent et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

MicroRNA-214 provokes cardiac hypertrophy via repression of EZH2

(2013) Tao Yang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Lethal myelofibrosis induced byBmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes

(2012) Hideyuki Oguro et al.   JOURNAL OF EXPERIMENTAL MEDICINE

In Search of CML Stem Cells’ Deadly Weakness

(2011) Francesca Pellicano et al.   Current Hematologic Malignancy Reports